PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC50 of 8.7 nM[1].
PDE9-IN-1 is excellent selectivity across PDE families[1].
PDE9-IN-1 (2.5 and 5.0 mg/kg; Oral administration; daily for 21 days) effectively recovers learning and memory function[1].
| Animal Model: | Unilateral common carotid artery occlusion (UCCAO) mouse model[1] |
| Dosage: | 2.5 and 5.0 mg/kg |
| Administration: | Oral administration; daily for 21 days |
| Result: | Significantly reduced the day 6 escape latency time and increased the frequency of platform area crossings, and recovered learning and memory function. High dose group possibly improved the escape latency time of mice. |
[1]. Wu Y, et al. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. J Med Chem. 2019 Apr 25;62(8):4218-4224.